A phase 2 study of NLX-112 for treating Spinocerebellar Ataxia.
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Befiradol (Primary)
- Indications Spinocerebellar ataxias
- Focus Therapeutic Use
- 03 Feb 2025 New trial record
Latest Information Update: 03 Feb 2025